 | Up a level |
König, D; Savic Prince, S; Hayoz, S; Zens, P; Berezowska, S; Jochum, W; Stauffer, E; Braunersreuther, V; Trachsel, B; Thierstein, S; Mark, M; Schmid, S; Curioni-Fontecedro, A; Addeo, A; Opitz, I; Guckenberger, M; Früh, M; Betticher, D C; Ris, H-B; Stupp, R; ... (2023). Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO open, 8(4), p. 101595. BMJ 10.1016/j.esmoop.2023.101595
Liem, Esmee Iml; Oddens, J R; Vernooij, Rwm; Li, R; Kamat, A M; Dinney, C P; Mengual, L; Alcaraz, A; Izquierdo, L; Savic, S; Thalmann, George; Bubendorf, L; Sylvester, R J; de Reijke, T M (2020). The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. The journal of urology, 203(2), pp. 283-291. Wolters Kluwer Health 10.1097/JU.0000000000000566
Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier
Koelzer, V H; Glatz, K; Bubendorf, L; Weber, A; Gaspert, A; Cathomas, G; Lugli, Alessandro; Zippelius, A; Kempf, W; Mertz, K D (2017). [The pathology of adverse events with immune checkpoint inhibitors]. Der Pathologe, 38(3), pp. 197-208. Springer 10.1007/s00292-017-0281-1
Berezowska, Sabina Anna; Schläfli, Anna; Adams, O; Galván Hernández, José Alberto; Bubendorf, L; Prince, S Savic; Schmid, Ralph; Gugger, M; Tschan, Mario; Langer, Rupert (2016). 25P Autophagy in early stage NSCLC - prognostic significance of the autophagy markers p62 and LC3B. Journal of thoracic oncology, 11(4Suppl), S66-S66. Elsevier 10.1016/S1556-0864(16)30139-3
D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2007). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of oncology, 19(4), pp. 739-745. Oxford: Oxford University Press 10.1093/annonc/mdm564
